<DOC>
	<DOCNO>NCT01526928</DOCNO>
	<brief_summary>Rociletinib novel , potent , small molecule irreversible tyrosine kinase inhibitor ( TKI ) selectively target mutant form epidermal growth factor receptor ( EGFR ) spar wild-type ( WT ) EGFR . The purpose study evaluate pharmacokinetic ( PK ) safety profile oral rociletinib ; determine maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) oral rociletinib ; ass safety efficacy rociletinib previously treat NSCLC patient know T790M EGFR mutation .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics , Efficacy Rociletinib ( CO-1686 ) Previously Treated Mutant Epidermal Growth Factor Receptor ( EGFR ) Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>Lung cancer remain common cancer worldwide non-small cell lung cancer account 85 % case . Cytotoxic chemotherapy mainstay patient NSCLC ; however , survival rate remain low toxicity significant . Molecularly targeted therapy prove superior chemotherapy NSCLC patient whose tumor mutation EGFR . Recent study establish tyrosine kinase inhibitor ( TKIs ) gold standard treat EGFR-mutation-positive NCSLC . However , patient TKIs eventually progress , approximately 50 % case , progression due development additional mutation call T790M . There currently approve therapy patient progress TKIs . Rociletinib may provide effective therapy patient population alternative treatment option . Nonclinical data demonstrate rociletinib inhibits T790M . It anticipate rociletinib may promote cell death tumor cell T790M mutation , thus provide possible therapeutic benefit patient develop T790M-mediated resistance first generation TKIs . This two-part , open-label study oral rociletinib administer daily previously treat NSCLC patient document evidence activate mutation EGFR gene fail treatment EGFR inhibitor erlotinib , gefitinib afatinib . This study include 2 part : Phase 1 ( complete enrolment ) : Dose-escalation Period 21-day cycle ; optional Treatment Extension Period start Day 22 Phase 2 ( currently enrol ) : Evaluation activity safety patient T790M EGFR mutation : Cohort A - Progressed EGFR direct therapy ( irrespective number order previous line NSCLC therapy ) Cohort B - Progression first single agent EGFR direct therapy receive also one previous line chemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion Criteria All patient must meet follow inclusion criterion : 1 . Metastatic unresectable locally advance NSCLC 2 . Evidence tumor one EGFR mutation exclude exon 20 insertion 3 . Biopsy either primary metastatic tumor tissue within 60 day dose 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 5 . Minimum age 18 year 6 . Adequate hematological biological function 7 . Written consent IRB/IECapproved Informed Consent Form ( ICF ) prior studyspecific evaluation Phase 2 Cohorts must also meet follow inclusion criterion : Disease progression confirm radiologic assessment treatment EGFR TKI Or Disease progression confirm radiologic assessment treatment first single agent EGFR TKI Documented evidence T790M mutation EGFR follow disease progression first single agent EGFR TKI . Measureable disease accord RECIST Version 1.1 Exclusion Criteria Any follow criterion exclude patient study participation : 1 . Documented evidence Exon 20 insertion activate mutation EGFR gene 2 . Active second malignancy 3 . Known preexist interstitial lung disease 4 . Patients Leptomeningeal carcinomatosis exclude . Other CNS metastasis permit treated , asymptomatic stable ( require steroid least 4 week prior start study treatment ) . 5 . Treatment prohibit medication less equal 14 day prior treatment rociletinib 6 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication start rociletinib 7 . Prior treatment rociletinib drug target T790M positive mutant EGFR spar wild type EGFR 8 . Certain cardiac abnormality history 9 . Nonstudy related surgical procedure less equal 7 day prior administration rociletinib 10 . Females pregnant breastfeed 11 . Refusal use adequate contraception fertile patient ( female male ) 12 week last dose rociletinib 12 . Presence serious unstable concomitant systemic disorder incompatible clinical study 13 . Any reason investigator considers patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>lung</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>T790M</keyword>
	<keyword>CO-1686</keyword>
	<keyword>unresectable</keyword>
	<keyword>recurrent</keyword>
	<keyword>EGFR-directed therapy</keyword>
	<keyword>irreversible EGFR inhibitor</keyword>
	<keyword>TIGER</keyword>
	<keyword>Rociletinib</keyword>
</DOC>